Rifampicin/isoniazid/pyrazinamide
Combination of | |
---|---|
Rifampicin | Rifamycin antibiotic |
Isoniazid | Anti-tuberculosis medication |
Pyrazinamide | Anti-tuberculosis medication |
Clinical data | |
Trade names | Rifater, Trifazid, others |
AHFS/Drugs.com | FDA Professional Drug Information |
License data | |
Pregnancy category |
|
Routes of administration | by mouth |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number |
|
PubChem CID | |
ChemSpider |
|
KEGG | |
Rifampicin/isoniazid/pyrazinamide, also known as rifampin/isoniazid/pyrazinamide, and sold under the trade name Rifater, is a medication used to treat tuberculosis.[1] It is a fixed dose combination of rifampicin, isoniazid, and pyrazinamide.[1] It is used either by itself or along with other antituberculosis medication.[1] It is taken by mouth.[1]
Side effects are those of the underlying medications.[1] These may include poor coordination, loss of appetite, nausea, joint pain, feeling tired, and numbness.[2] Severe side effects include liver problems.[3] Use in those under the age of 15 may not be appropriate.[3] It is unclear if use in pregnancy is safe for the baby.[3]
Rifampicin/isoniazid/pyrazinamide was approved for medical use in the United States in 1994.[3] It is on the World Health Organization's List of Essential Medicines.[4]
Medical uses[]
The hope of a fixed-dose combination pill is to increase the likelihood that people will take all of three medications.[5] Also, if people forget to take one or two of their drugs, they might not then develop resistance to the remaining drugs.
Society and culture[]
It is manufactured by Aventis.[citation needed]
See also[]
- Tuberculosis treatment
- Rifampicin + isoniazid + ethambutol
References[]
- ^ Jump up to: a b c d e World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 143. hdl:10665/44053. ISBN 9789241547659.
- ^ "Rifater Side Effects in Detail - Drugs.com". www.drugs.com. Archived from the original on 21 December 2016. Retrieved 18 December 2016.
- ^ Jump up to: a b c d "Rifater - FDA prescribing information, side effects and uses". www.drugs.com. October 2016. Archived from the original on 21 December 2016. Retrieved 18 December 2016.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ Brown, Morris J.; Sharma, Pankaj; Bennett, Peter N. (30 July 2012). Clinical Pharmacology. Elsevier Health Sciences. p. 204. ISBN 978-0-7020-5113-5.
- Anti-tuberculosis drugs
- Combination drugs
- Rifamycin antibiotics
- Sanofi
- World Health Organization essential medicines
- Antiinfective agent stubs